9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Estimated reading time: < 1 min

Condition: Solid Tumors

Estimated Enrollment: 205

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Safety and tolerability of CB-839: Incidence of adverse events,  Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood,  Pharmacodynamics: % inhibition of glutaminase in blood, Clinical activity: Change in tumor volume from baseline

Interventions: CB-839, Pac-CB

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 2019

Completion Date: September 2019

Last  Posted Date: July 19, 2018

Location: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02071862

Was this article helpful?
Dislike 0